stockrowBecton, Dickinson and Company
BDX Healthcare Medical Instruments & Supplies
Becton, Dickinson and Company’s revenue for fiscal 2025 (year ended September 2025) was $21.8 billion, up 8.24% from fiscal 2024.
- Revenue
- −9.55%
- EPS
- −31.5%
- Free cash flow
- −31.6%
- Total debt
- −22.9%
Quarter to June 2026, against a year earlier
Follow BDX
Alert me
Becton, Dickinson and Company (BDX) EPS (diluted)
Becton, Dickinson and Company's EPS (diluted) for fiscal 2025 was $5.82, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $3.32. Over the past ten years it has ranged from $0.60 (fiscal 2018) to $6.85 (fiscal 2021); the current reading is higher than 73% of that period. Becton, Dickinson and Company ranks 8th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.82 | (1.85%) |
| FY2024 | $5.93 | 20.04% |
| FY2023 | $4.94 | (15.99%) |
| FY2022 | $5.88 | (14.16%) |
| FY2021 | $6.85 | 152.77% |
| FY2020 | $2.71 | (30.33%) |
| FY2019 | $3.89 | 548.33% |
| FY2018 | $0.60 | (86.96%) |
| FY2017 | $4.60 | 2.45% |
| FY2016 | $4.49 | 34.03% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $1.37 | — |
| Mar 2026 | −$1.11 | — |
| Dec 2025 | $1.34 | (22.09%) |
| Sep 2025 | $1.72 | (14.00%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| RMD ResMed Inc. compare | $10.98 |
| WST West Pharmaceutical Services, Inc. compare | $8.91 |
| ISRG Intuitive Surgical, Inc. compare | $8.27 |
| BDX Becton, Dickinson and Company | $3.32 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| ALC Alcon compare | $1.31 |
| SOLV Solventum Corporation compare | $0.89 |
| MDLN Medline Inc. compare | $0.68 |
| BAX Baxter International Inc. compare | −$1.41 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement